Koordinierungszentrum für Klinische Studien der Philipps-Universität Marburg

Publikationen 2013

Bauerschlag, D. O., Hilpert, F., Meier, W., Rau, J., Meinhold-Heerlein, I., Maass, N., Dubois, A., Sehouli, J., Arnold, N., Schem, C., Oberg, H. H. & Baumann, K. 2013. Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients. Transl Oncol. 2013 Jun 1;6(3):305-10

Deuschl, G., Schupbach, M., Knudsen, K., Pinsker, M. O., Cornu, P., Rau, J., Agid, Y. & Schade-Brittinger, C. 2013. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord, 19(1), 56-61.

Dodel, R., Schade-Brittinger, C. & Diener, H. C. 2013. Worauf kommt es beim Lesen von Therapiestudien an? Akt Neurol, 36(01), 22-28.

du Bois, A., Ewald-Riegler, N., De Gregorio, N., Reuss, A., Mahner, S., Fotopoulou, C., Kommoss, F., Schmalfeldt, B., Hilpert, F., Fehm, T., Burges, A., Meier, W., Hillemanns, P., Hanker, L., Hasenburg, A., Strauss, H. G., Hellriegel, M., Wimberger, P., Keyver-Paik, M. D., Baumann, K., Canzler, U., Wollschlaeger, K., Forner, D., Pfisterer, J., Schroder, W., Munstedt, K., Richter, B., Kommoss, S. & Hauptmann, S. 2013. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. Eur J Cancer. 2013 Mar 11, 49, 1905-1914

Fensterer, H., Schade-Brittinger, C., Muller, H. H., Tebbe, S., Fass, J., Lindig, U., Settmacher, U., Schmidt, W. E., Marten, A., Ebert, M. P., Kornmann, M., Hofheinz, R., Endlicher, E., Brendel, C., Barth, P. J., Bartsch, D. K., Michl, P. & Gress, T. M. 2013. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Ann Oncol. 2013 Oct;24(10):2576-81

Harter, P., Sehouli, J., Kimmig, R., Rau, J., Hilpert, F., Kurzeder, C., Elser, G. & Du Bois, A. 2013. Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). Invest New Drugs (2013) 31:1499–1504.

Mahner, S., Eulenburg, C., Staehle, A., Wegscheider, K., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., Pfisterer, J. & Du Bois, A. 2013. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer, 49(1), 142-9.

Schuepbach, W. M. M*., Rau, J*., Knudsen, K*., Volkmann, J., Krack, P., Timmermann, L., Hälbig, T. D., Hesekamp, H., Navarro, S. M., Meier, N., Falk, D., Mehdorn, M., Paschen, S., Maarouf, M., Barbe, M. T., Fink, G. R., Kupsch, A., Gruber, D., Schneider, G.-H., Seigneuret, E., Kistner, A., Chaynes, P., Ory-Magne, F., Brefel Courbon, C., Vesper, J., Schnitzler, A., Wojtecki, L., Houeto, J.-L., Bataille, B., Maltête, D., Damier, P., Raoul, S., Sixel-Doering, F., Hellwig, D., Gharabaghi, A., Krüger, R., Pinsker, M. O., Amtage, F., Régis, J.-M., Witjas, T., Thobois, S., Mertens, P., Kloss, M., Hartmann, A., Oertel, W. H., Post, B., Speelman, H., Agid, Y.*, Schade-Brittinger, C.* & Deuschl, G.* 2013. Neurostimulation for Parkinson's Disease with Early Motor Complications. New England Journal of Medicine, 368(7), 610-622. (*shared authorship)

Zipfel S, Wild B, Groß G, Friederich HC, Teufel M, Schellberg D, Giel KE, de Zwaan M, Dinkel A, Herpertz S, Burgmer M, Löwe B, Tagay S, von Wietersheim J, Zeeck A, Schade-Brittinger C, Schauenburg H, Herzog W. Focal psychodynamic therapy, cognitive behaviour therapy, and optimised treatment as usual in outpatients with anorexia nervosa (ANTOP study): randomised controlled trial. The Lancet 14 October 2013 (Article in Press DOI: 10.1016/S0140-6736(13)61746-8)

Deuschl G, Schade-Brittinger C, Agid Y. 2013 Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. May 23;368(21):2038. (letter)

Heitz F, du Bois A, Harter P, Lubbe D, Kurzeder C, Vergote I, Plante M, Pfisterer J. 2013. Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol. 2013 Jun;129(3):463-6

Swierkot K, Brusius M, Leismann D, Nonnenmacher C, Nüsing R, Lubbe D, Schade-Brittinger C, Mengel R. 2013 Manual versus sonic-powered toothbrushing for plaque reduction in patients with dental implants: an explanatory randomised controlled trial. Eur J Oral Implantol. 2013;6(2):133-44.

Ohmann C, Canham S, Cornu C, Dreß J, Gueyffier F, Kuchinke W, Nicolis EB, Wittenberg M. Revising the ECRIN standard requirements for information technology and data management in clinical trials. Trials 2013, 14:97. Open access: http://www.trialsjournal.com/content/14/1/97

Funck RC, Mueller HH, Lunati M, Piorkowski C, De Roy L, Paul V, Wittenberg M, Wuensch D, Blanc JJ; for the BioPace study group. Characteristics of a large sample of candidates for permanent ventricular pacing included in the Biventricular Pacing for Atrio-ventricular Block to Prevent Cardiac Desynchronization Study (BioPace). Europace. 2013 Nov 7. [Epub ahead of print]

Arnold R, Wittenberg M, Rinke A, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, Mueller HH, PROMID Study Group. Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results on long-term survival. J Clin Oncol 31, 2013 (suppl; abstr 4030)